- Home
- TRIB vs BCAB Comparison
TRIB vs BCAB Comparison
Compare TRIB & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRIB
- BCAB
- Stock Information
- Founded
- TRIB 1992
- BCAB 2007
- Country
- TRIB Ireland
- BCAB United States
- Employees
- TRIB N/A
- BCAB N/A
- Industry
- TRIB Biotechnology: In Vitro & In Vivo Diagnostic Substances
- BCAB Medicinal Chemicals and Botanical Products
- Sector
- TRIB Health Care
- BCAB Health Care
- Exchange
- TRIB Nasdaq
- BCAB Nasdaq
- Market Cap
- TRIB 25.5M
- BCAB 27.0M
- IPO Year
- TRIB N/A
- BCAB 2020
- Fundamental
- Price
- TRIB $0.59
- BCAB $0.34
- Analyst Decision
- TRIB
- BCAB Buy
- Analyst Count
- TRIB 0
- BCAB 2
- Target Price
- TRIB N/A
- BCAB $1.00
- AVG Volume (30 Days)
- TRIB 37.2K
- BCAB 631.0K
- Earning Date
- TRIB 05-22-2025
- BCAB 03-27-2025
- Dividend Yield
- TRIB N/A
- BCAB N/A
- EPS Growth
- TRIB N/A
- BCAB N/A
- EPS
- TRIB N/A
- BCAB N/A
- Revenue
- TRIB $59,126,000.00
- BCAB $11,000,000.00
- Revenue This Year
- TRIB $11.63
- BCAB N/A
- Revenue Next Year
- TRIB $10.13
- BCAB N/A
- P/E Ratio
- TRIB N/A
- BCAB N/A
- Revenue Growth
- TRIB N/A
- BCAB N/A
- 52 Week Low
- TRIB $0.56
- BCAB $0.24
- 52 Week High
- TRIB $3.55
- BCAB $4.02
- Technical
- Relative Strength Index (RSI)
- TRIB 36.73
- BCAB 41.83
- Support Level
- TRIB $0.56
- BCAB $0.28
- Resistance Level
- TRIB $0.71
- BCAB $0.40
- Average True Range (ATR)
- TRIB 0.04
- BCAB 0.04
- MACD
- TRIB -0.01
- BCAB 0.01
- Stochastic Oscillator
- TRIB 15.62
- BCAB 48.29
About TRIB Trinity Biotech plc
Trinity Biotech PLC is in the business of developing, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point-of-care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Immublot, and others. Geographically, it has two segments namely the Americas, and the Rest of World - Ireland from which it derives a majority of its revenue from the Americas segment.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.